Should You Buy MDxHealth SA (MDXH) Today? Analysis, Price Targets, and 2026 Outlook.
No data
No data
Growth
Profitability
Efficiency
Wall Street analysts forecast MDXH stock price to rise
5 Analyst Rating
Wall Street analysts forecast MDXH stock price to rise
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.483
Low
7
Averages
7.67
High
9
Current: 0.483
Low
7
Averages
7.67
High
9
William Blair
Outperform -> Market Perform
downgrade
$NULL
AI Analysis
2026-05-14
Reason
William Blair
Price Target
$NULL
AI Analysis
2026-05-14
downgrade
Outperform -> Market Perform
Reason
William Blair downgraded MDxHealth to Market Perform from Outperform without a price target. The company's Q1 revenue came in well below expectations and its full-year revenue guidance was cut by just under 20% at the midpoint, the analyst tells investors in a research note. The firm says given the given the uncertainty associated with the reimbursement environment for Resolve in this non-MolDX jurisdiction, MDxHealth is exiting the Resolve business and closing the Texas lab. "This is at least a near-term shock to the thesis," the firm says.
Lake Street
analyst
Buy
downgrade
$9 -> $5
2026-05-14
Reason
Lake Street
analyst
Price Target
$9 -> $5
2026-05-14
downgrade
Buy
Reason
Lake Street lowered the firm's price target on MDxHealth to $5 from $9 and keeps a Buy rating on the shares. MDxHealth announced its Q1 results and the discontinuation of its Resolve UTI business following an unexplained policy reversal by Novitas, notes the analyst, who says the "headline is the strategic exit, not the print." MDxHealth reset 2026 revenue guidance to to reflect the Resolve exit, adds the analyst, who remains confident in the future of the core prostate cancer business but realizes "management will be in the penalty box for a quarter or two as these changes are absorbed and performance is demonstrated."
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MDXH
